The FDA’s regulation of medicinal cannabidiol containing products is an ongoing work in progress. However, the FDA’s recent spate of Warning Letters demonstrates that companies selling CBD products need to exercise caution when making promotional claims.
Related Posts
Read the full article in the September issue of Policy and Medicine Compliance Update https://complianceupdate.policymed.com/september-2019-policy-medicine-compliance-update/